Rheumatology Advance Access originally published online on January 28, 2008
Rheumatology 2008 47(3):381-382; doi:10.1093/rheumatology/kem381
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial
Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital. Chapeltown Road, Leeds LS7 4SA, UK
Correspondence to: P. J. Kotyla, Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital. Chapeltown Road, Leeds LS7 4SA, UK. E-mail: pkotyla@slam.katowice.pl
| The first 10% of the full text of this article appears below. |
SIR, I have read with the interest the paper by Dr Ferreira and colleagues [1] regarding the therapeutic potential of atorvastatin in restoration of impaired endothelial function in patients with SLE. As the authors pointed out in their